Physician profile
William B Shay
NPI 1922042639
$7,182.29
in general payments reported to CMS, 2019-2025
32 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $1,141 · 2021: $876 · 2022: $830 · 2023: $1,230 · 2024: $887 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,005 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,005.48 |
| Education | $119.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,430.21 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $877.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $812.92 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $567.27 | 2019-2023 | Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $455.93 | 2022-2025 | |
| Abbvie INC. | $399.22 | 2020-2025 | Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.71 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $336.02 | 2019-2025 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $236.66 | 2019-2023 | Veozah |
| Janssen Pharmaceuticals, INC | $178.28 | 2019-2022 | |
| Philips North America LLC | $165.51 | 2020-2023 | |
| Nevro Corp. | $139.57 | 2023 | Senza |
| Pfizer INC. | $131.15 | 2019-2025 | |
| Medtronic, INC. | $124.52 | 2023 | Intellis Adaptivestim |
| Allergan, INC. | $118.07 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $117.25 | 2021-2023 | Livalo, Seglentis |
| Radius Health, INC. | $111.26 | 2020-2024 | Tymlos |
| Sanofi-Aventis U.S. LLC | $74.44 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.11 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.14 | 2020-2022 | |
| Glaxosmithkline, LLC. | $63.55 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boston Scientific Corporation | $57.33 | 2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $54.48 | 2019-2021 | |
| Abbott Laboratories | $48.81 | 2021-2022 | |
| Esperion Therapeutics, INC. | $38.80 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $29.60 | 2021 | |
| Exact Sciences Corporation | $21.57 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $19.26 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $16.93 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.18 | 2025 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $14.18 | 2023 | Quviviq |
| Amarin Pharma, INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Shay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.